Trial Profile
A randomized, double-blind comparison of LY2140023, olanzapine, and placebo in the treatment of patients with schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Pomaglumetad methionil (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Denovo Biopharma; Eli Lilly and Company
- 03 Aug 2006 Status change
- 08 Feb 2006 New trial record.